Starodub Alexander - Health Goshen Center for Cancer Care, Indiana University

基本信息

浏览量：94

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 110 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

698 A Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120 (4–1BB X PD-L1 BsAb) in Patients with Advanced or Metastatic Solid Tumors

Dong-Wan Kim,Hye Ryun Kim, Se-Hoon Lee,Se Hyun Kim, Jae Lyun Lee, Minal Barve,Alexander Starodub,John Sarantopoulos, Seong-jung Kim, Sooa Jung, Taewan Kim,Jiyeon Yoon, Heera Roh, Yesong Shin,Hyunjin Kim, Eunhye Baek, Young Su Noh

Regular and Young Investigator Award Abstracts (2024)

引用0浏览0引用

Abstract CT168: A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 (a HER3-targeting ADC) in Patients with Advanced/metastatic Solid Tumors

Aaron Lisberg,Shun Lu,Alexander Starodub,Harshad Amin,Julia Rotow,Lin Wu, Alexander I. Spira,Erika Hamilton, Weidi Shen, Liming Li, Zhongyuan Zhu, Wanyi Gu,Yang Qiu,Rong Shi, Shengxue Liu

Cancer researchno. 7_Supplement (2024): CT168-CT168

引用0浏览0引用

Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 b/g alone or in combination with pembrolizumab: Initial results from dose escalation

Alexander Starodub,John D. Powderly,Sung-Bae Kim,Diwakar Davar,Andrew Graham Hill,Oladapo O. Yeku,Nashat Y. Gabrail, Christian Krapp, Susanne Pihl,Ying Zhang,Sibel Slavsky,Davis Y. Torrejon Castro,Anne Uyei,Stina Mui Singel,Vineet Kwatra

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023): e14597-e14597

引用0浏览0引用

1073 A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRJ1–3024in subjects with advanced solid tumors

Yang Xu,Alexander Starodub,Cesar Perez,Yuping Li,Andrae Vandross,Jason Henry, Alexander I Spira,Xuebin Liao

Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)

引用0浏览0引用

Supplementary Figure 2 from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma

Sumanta K. Pal,Arun Azad,Shailender Bhatia, Harry A. Drabkin,Brian A. Costello,John Sarantopoulos,Ravindran Kanesvaran,Richard T. Lauer,Alexander Starodub,Ralph J. Hauke, Christopher J. Sweeney,Noah M. Hahn,Guru Sonpavde,Stephen Richey, T. H. Breen,Gabriel Kremmidiotis,Annabell F. Leske,Elizabeth Doolin,David C. Bibby,Jeremy C. Simpson, J. Iglesias, Thomas E. Hutson

openalex（2023）

引用0浏览0引用

1034P Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy

A.N. Starodub,S-B. Kim,D. Davar,J. Powderly, A.G. Hill,O. Yeku,N. Gabrail, C. Krapp, S. Pihl, M. Chen, S. Slavsky,D. Torrejon Castro,S.M. Singel,V. Kwatra

Annals of Oncology (2023): S628-S628

引用0浏览0引用

Supplemental Figure 1 from First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

Alexander N. Starodub,Allyson J. Ocean,Manish A. Shah,Michael J. Guarino, Vincent J. Picozzi,Linda T. Vahdat,Sajeve S. Thomas,Serengulam V. Govindan,Pius P. Maliakal,William A. Wegener,Steven A. Hamburger,Robert M. Sharkey,David M. Goldenberg

crossref（2023）

引用0浏览0引用

A Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Stephen D. Smith,Alexander Starodub,Don A. Stevens,Aditi Shastri,Pierluigi Porcu,Tatyana Feldman,Reggie Ewesuedo,Chris DeSavi,Joyoti Dey,Sagar Agarwal,Sean Donohue,Rachelle Perea,Christine Klaus,Jared Gollob

Hematological Oncology（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn